全文获取类型
收费全文 | 166篇 |
免费 | 19篇 |
国内免费 | 5篇 |
专业分类
儿科学 | 1篇 |
妇产科学 | 4篇 |
基础医学 | 26篇 |
口腔科学 | 3篇 |
临床医学 | 11篇 |
内科学 | 46篇 |
皮肤病学 | 1篇 |
神经病学 | 8篇 |
外科学 | 5篇 |
综合类 | 23篇 |
预防医学 | 2篇 |
眼科学 | 2篇 |
药学 | 11篇 |
中国医学 | 2篇 |
肿瘤学 | 45篇 |
出版年
2023年 | 5篇 |
2022年 | 11篇 |
2021年 | 14篇 |
2020年 | 15篇 |
2019年 | 10篇 |
2018年 | 7篇 |
2017年 | 14篇 |
2016年 | 12篇 |
2015年 | 23篇 |
2014年 | 20篇 |
2013年 | 4篇 |
2012年 | 10篇 |
2011年 | 13篇 |
2010年 | 9篇 |
2009年 | 2篇 |
2008年 | 1篇 |
2007年 | 3篇 |
2006年 | 4篇 |
2004年 | 2篇 |
2003年 | 1篇 |
2002年 | 1篇 |
2000年 | 1篇 |
1999年 | 1篇 |
1993年 | 1篇 |
1990年 | 1篇 |
1985年 | 2篇 |
1984年 | 2篇 |
1979年 | 1篇 |
排序方式: 共有190条查询结果,搜索用时 156 毫秒
1.
Michael L. Nickerson Kate M. Im Kevin J. Misner Wei Tan Hong Lou Bert Gold David W. Wells Hector C. Bravo Karin M. Fredrikson Timothy T. Harkins Patrice Milos Berton Zbar W. Marston Linehan Meredith Yeager Thorkell Andresson Michael Dean G. Steven Bova 《Human mutation》2013,34(9):1231-1241
Metastatic castration‐resistant prostate cancer (mCRPC) is a lethal disease, and molecular markers that differentiate indolent from aggressive subtypes are needed. We sequenced the exomes of five metastatic tumors and healthy kidney tissue from an index case with mCRPC to identify lesions associated with disease progression and metastasis. An Ashkenazi Jewish (AJ) germline founder mutation, del185AG in BRCA1, was observed and AJ ancestry was confirmed. Sixty‐two somatic variants altered proteins in tumors, including cancer‐associated genes, TMPRSS2‐ERG, PBRM1, and TET2. The majority (n = 53) of somatic variants were present in all metastases and only a subset (n = 31) was observed in the primary tumor. Integrating tumor next‐generation sequencing and DNA copy number showed somatic loss of BRCA1 and TMPRSS2‐ERG. We sequenced 19 genes with deleterious mutations in the index case in additional mCRPC samples and detected a frameshift, two somatic missense alterations, tumor loss of heterozygosity, and combinations of germline missense SNPs in TET2. In summary, genetic analysis of metastases from an index case permitted us to infer a chronology for the clonal spread of disease based on sequential accrual of somatic lesions. The role of TET2 in mCRPC deserves additional analysis and may define a subset of metastatic disease. 相似文献
2.
Wei Zhang Zonghong Shao Rong Fu Huaquan Wang Lijuan Li Hui Liu 《International journal of clinical and experimental pathology》2015,8(9):10840-10846
Aims and background: To investigate the expressions of TET2 mRNA in bone marrow CD3+ and CD34+ cells of the patients with myelodysplastic syndromes (MDS) and to study the effect of silencing TET2 by small interfering RNA (siRNA) on the biological characteristics of CD34+ cells. Methods: CD3+ and CD34+ cells were sorted by magnetic activated cell-sorting system from bone marrow of MDS patients and controls. The mRNA expressions of TET2 in bone marrow CD3+ and CD34+ cells of 28 MDS patients and 20 controls were detected by qPCR. The silencing effect of RNA interference (RNAi) on TET2 expression in CD34+ bone marrow cells of normal control was identified by qPCR and Western blot analysis. The cell cycle kinetics and cell apoptosis were then detected by flow cytometry. Results: The expression of TET2 mRNA in CD3+ and CD34+ cells was down-regulated in MDS compared with that in controls [(0.16±0.11) vs. (1.05±0.32) (P<0.001); (0.58±0.26) vs. (1.25±0.94) (P<0.005)]. The siRNA targeting TET2 suppressed the expression of TET2 in normal CD34+ cells. Meanwhile, the proliferation activity was significantly enhanced [G0/G1: (87.82±8.25)% vs. (92.65±7.06)% and (93.60±5.54)%, P<0.05; S: (11.50±8.31)% vs. (6.92±7.04)% and (5.95±5.53)%, P<0.05] and the apoptosis rate was declined [(21.28±9.73)% vs. (26.17±9.88)% and (26.20±9.78)%] in the cells which transfected with TET2 siRNA as compared to those in the cells transfected with scrambled siRNA and control cells. Conclusions: The TET2 expression of in CD3+ and CD34+ cells of MDS patients was decreased. Suppression of TET2 expression renders the CD34+ cells harboring more aggressive phenotype. This preliminary finding suggests that CD34+ cells lowering expression of TET2 may play an oncogenic role on myeloid tumor and CD3+ T cells of MDS patients may be derived from the malignant clone. 相似文献
3.
Hywyn Churchill Harris Naina Richard Boriack Dinesh Rakheja Weina Chen 《International journal of clinical and experimental pathology》2015,8(9):11753-11759
Objectives: Angioimmunoblastic T-cell lymphoma (AITL) is an aggressive peripheral T-cell lymphoma with mutations in genes encoding isocitrate dehydrogenase1 and 2 (IDH1 and IDH2). Mutant IDH generates the oncometabolite D-2-hydroxyglutarate (D-2HG). We report the first case of discordant intracellular and plasma D-2HG levels in a patient with IDH2 R172S mutated AITL. Methods: An 87-year-old woman was diagnosed with AITL in the groin lymph node by morphologic and immunophenotypic analyses, and molecular studies by DNA sequencing. D-2HG was measured in both tumoral tissue and in pre-treatment plasma by liquid chromatography-tandem mass spectrometry. Results: While D-2HG was markedly elevated in the tissue sample, its level in plasma was normal. We discuss this discordant D-2HG result within the context of previously reported discordant 2HG results in other IDH mutated tumors, and its implication for using circulating D-2HG as a biomarker of IDH mutation. In addition, this case also harbored mutations in RHOA, TET2, and TP53. The molecular pathogenesis is briefly discussed. Conclusion: While our case suggests that circulating D-2HG is not a reliable marker of IDH mutation in AITL, more cases need to be studied to arrive at a definite conclusion. 相似文献
4.
5.
目的探讨TET对宫颈癌HeLa细胞增殖和侵袭的作用及其调控机制。方法siRNA敲低宫颈癌HeLa细胞中TET的表达。细胞计数法、克隆形成实验、Transwell侵袭实验检测TET对宫颈癌HeLa细胞增殖、克隆形成及侵袭能力的影响。TargetScan软件预测TET与miR-26a之间的结合位点,qRT-PCR和双荧光素酶报告基因实验检测TET与miR-26之间的关系。结果TET敲低抑制宫颈癌HeLa细胞增殖、克隆形成及侵袭能力。经预测miR-26a与TET1、TET2和TET3之间均存在结合位点;共转染野生型TET和miR-26a模拟物可降低荧光素酶活性;转染miR-26a抑制HeLa细胞中TET的表达。结论miR-26a通过下调TET1、TET2和TET3的表达而抑制宫颈癌HeLa细胞增殖与侵袭能力。 相似文献
6.
7.
Viktória Koroknai István Szász Hector Hernandez-Vargas Nora Fernandez-Jimenez Cyrille Cuenin Zdenko Herceg Laura Vízkeleti Róza Ádány Szilvia Ecsedi Margit Balázs 《Experimental dermatology》2020,29(1):39-50
Tumor cell invasion is one of the key processes during cancer progression, leading to life-threatening metastatic lesions in melanoma. As methylation of cancer-related genes plays a fundamental role during tumorigenesis and may lead to cellular plasticity which promotes invasion, our aim was to identify novel epigenetic markers on selected invasive melanoma cells. Using Illumina BeadChip assays and Affymetrix Human Gene 1.0 microarrays, we explored the DNA methylation landscape of selected invasive melanoma cells and examined the impact of DNA methylation on gene expression patterns. Our data revealed predominantly hypermethylated genes in the invasive cells affecting the neural crest differentiation pathway and regulation of the actin cytoskeleton. Integrative analysis of the methylation and gene expression profiles resulted in a cohort of hypermethylated genes (IL12RB2, LYPD6B, CHL1, SLC9A3, BAALC, FAM213A, SORCS1, GPR158, FBN1 and ADORA2B) with decreased expression. On the other hand, hypermethylation in the gene body of the EGFR and RBP4 genes was positively correlated with overexpression of the genes. We identified several methylation changes that can have role during melanoma progression, including hypermethylation of the promoter regions of the ARHGAP22 and NAV2 genes that are commonly altered in locally invasive primary melanomas as well as during metastasis. Interestingly, the down-regulation of the methylcytosine dioxygenase TET2 gene, which regulates DNA methylation, was associated with hypermethylated promoter region of the gene. This can probably lead to the observed global hypermethylation pattern of invasive cells and might be one of the key changes during the development of malignant melanoma cells. 相似文献
8.
Jie Deng Huan-Huan Ding Jia-Li Long Su-Yan Lin Meng Liu Xue-Qin Zhang Wen-Jun Xin Xiangcai Ruan 《International journal of cancer. Journal international du cancer》2020,147(9):2503-2514
Chemotherapy-induced neuropathic pain is a common dose-limiting side effect of cancer treatment but the underlying mechanisms are largely unknown. Here, we used a whole-genome expression microarray and gene ontology analysis to identify the upregulation of a sequence-specific DNA-binding protein, HOXA6, in the spinal dorsal horn on Day 10 after injection of rats with oxaliplatin. Genetic disruption of HOXA6 with siRNAs alleviated mechanical allodynia after oxaliplatin administration. Reduced representation bisulfite sequencing assays indicated that oxaliplatin decreased the methylation levels of the SOX10 promoter but not of HOXA6. TET1 was also upregulated by oxaliplatin. Genetic disruption of TET1 with siRNA blocked the promoter demethylation of SOX10 and the upregulation of HOXA6 and SOX10. Importantly, inhibition of SOX10 by intrathecal application of SOX10 siRNA ameliorated the mechanical allodynia induced by oxaliplatin and downregulated the expression of HOXA6. Consistently, overexpression of SOX10 through intraspinal injection of AAV-SOX10-EGFP produced mechanical allodynia and upregulated the expression of spinal dorsal horn HOXA6. Moreover, chromatin immunoprecipitation assays demonstrated that oxaliplatin increased the binding of SOX10 to the promoter region of HOXA6. Taken together, our data suggest that HOXA6 upregulation through the TET1-mediated promoter demethylation of SOX10 may contribute to oxaliplatin-induced neuropathic pain. 相似文献
9.
Lukas Chavez Yun Huang Khai Luong Suneet Agarwal Lakshminarayan M. Iyer William A. Pastor Virginia K. Hench Sylvia A. Frazier-Bowers Evgenia Korol Shuo Liu Mamta Tahiliani Yinsheng Wang Tyson A. Clark Jonas Korlach Patricia J. Pukkila L. Aravind Anjana Rao 《Proceedings of the National Academy of Sciences of the United States of America》2014,111(48):E5149-E5158
10.